|Videos|May 25, 2023
Efficacy of Immunotherapies for dMMR or MMRp Advanced/Recurrent Endometrial Cancer
The panel discusses their opinions on the use of immunotherapy in different populations of women with advanced/recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
5